GlassScriptPhysician profile
Carol L Anders
NPI 1063406338
$3,203.44
in general payments reported to CMS, 2019-2025
20 companies · $850 in 2025
The $850 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $588 · 2023: $545 · 2024: $882 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $443.92 | 2021-2025 | Breztri, Tezspire, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.04 | 2021-2025 | Xifaxan |
| Amgen INC. | $294.32 | 2024-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $277.94 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $224.36 | 2024 | Ajovy, Austedo Xr |
| Neurocrine Biosciences, INC. | $194.02 | 2023-2024 | Ingrezza |
| Novo Nordisk INC | $185.43 | 2022-2023 | Wegovy |
| Paratek Pharmaceuticals, INC. | $138.03 | 2023-2024 | Nuzyra |
| Gilead Sciences, INC. | $116.98 | 2025 | |
| Sk Life Science, INC. | $116.63 | 2025 | Xcopri |
| Ani Pharmaceuticals, INC. | $112.58 | 2025 | Purified Cortrophin Gel |
| Eisai INC. | $109.22 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $99.75 | 2025 | |
| Sumitomo Pharma America, INC. | $87.32 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $77.55 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $73.34 | 2021 | |
| Genentech USA, INC. | $65.93 | 2021 | |
| Axsome Therapeutics, INC. | $61.51 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $57.61 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.